Ligand Pharmaceuticals Raises 2026 Adjusted EPS Guidance Amid Strong Royalty Growth
Ligand Pharmaceuticals (LGND) has raised its adjusted earnings per share (EPS) guidance for 2026 to a range of $9.50 to $9.75. This upward revision follows a strong third quarter where the company reported a significant 51% year-over-year increase in royalty revenue, reaching approximately $70 million. In addition to the improved earnings outlook, management announced plans to target approximately $200 million in annual capital deployment. The company's leadership expressed confidence in its financial trajectory driven by robust royalty streams and strategic capital allocation.
Tickers: $LGND